Open an account

Lite Strategy

LITS · NASDAQ

$1.19+$0.03 (+2.59%)TodayMarket closed ·
Prev close $1.16

About LITS

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.

Employees
4
Headquarters
San Diego, California
Listed
Dec 18, 2003
Sector
Health Care
Industry
Biotechnology
Website
litestrategy.com

LITS key statistics

Market cap
36.18M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
905.54K
Volume
225.25K
Open price
$1.16
High today
$1.23
Low today
$1.13
52 Week high
$2.26
52 Week low
$0.6888

Lite Strategy (LITS) at a glance

As of Oct 20, 2026, Lite Strategy (LITS) shares are priced at $1.19, giving the company a market cap of 36.18M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.13 and $1.23. The current price is 5.3% above the day's low and 3.3% below its high.

Volume so far is 225.25K shares, below the average of 905.54K shares a day.

Over the past year Lite Strategy has ranged from $0.6888 to $2.26, and now sits 32% of the way up that range.

Lite Strategy met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY24 it reported -$2.76 per share against an estimate of -$1.46.

LITS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 122.1% on average.

  1. Q1 FY23: reported -$2.40 per share against an estimate of -$2.92
  2. Q2 FY23: reported $1.60 per share against an estimate of -$3.06
  3. Q3 FY23: reported -$2.32 per share against an estimate of -$2.92
  4. Q4 FY23: reported -$1.51 per share against an estimate of -$2.46
  5. Q1 FY24: reported $8.46 per share against an estimate of -$2.16
  6. Q2 FY24: reported -$1.66 per share against an estimate of -$1.35
  7. Q3 FY24: reported -$1.37 per share against an estimate of -$1.55
  8. Q4 FY24: reported -$2.76 per share against an estimate of -$1.46

LITS news

  • Press releaseGlobe Newswire

    Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseBusiness Wire

    MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'

Similar companies

Companies in the same industry as Lite Strategy

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.